News

BMY

Portola Gets FDA Accelerated Approval for Andexxa to Treat Life-Threatening Bleeding

Edward Kim | Equities.com |

Points for persistence as the FDA had initially rejected the drug in 2016.


American Journal of Hematology Publishes Positive Data on Rigel's Immune Thrombocytopenia Drug

Edward Kim | Equities.com |

Rigel's Tavalisse, approved 2 weeks ago, showed "clinically‐meaningful responses in ITP patients."


ASLAN Pharmaceuticals' US IPO Expected Next Week

Edward Kim | Equities.com |

Singapore-based oncology-focused company targeting diseases that are both highly prevalent in Asia and that have orphan indications in the US and Europe.


Arcus Biosciences Presents Positive Data on Lead Cancer Therapeutic

Edward Kim | Equities.com |

Lead program targets the adenosine pathway -- critical to the immunosuppression response in tumors.


​Healthy Bets in Oncology: Bristol-Myers Squibb and AstraZeneca

MoneyShow | Equities.com |

Two leading players in the pharmaceutical sector present opportunities in the space of oncology.


Jnana Therapeutics Launches With $50 Million Series A

Edward Kim | Equities.com |

Jnana is targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates (Image: Indiamart)


​Drug Stocks Attractive for DRIP Investors

MoneyShow | Equities.com |

One sector that has recovered nicely this year after a miserable 2016 is pharmaceuticals.


​OncoSec Is Steadily Taking Its Place as a Leader in Immuno-Oncology

Spotlight Companies | Equities.com |

The company continues to string one milestone after another.


​Here's What the Bristol-Myers Squibb Means For Halozyme Therapeutics

Mark Collins | Equities.com |

Bristol Myers-Squibb and Roche just validated Halozyme's proprietary technology in the same day. Here's what this means for the company.


​Top Dividend Picks for the Next 25 Years

MoneyShow | Equities.com |

Each of these names should continue to be decent wealth-builders over the next quarter century.


Sponsored Financial Content

Market Movers